Trends and Outcomes of Non-compliance with Treatment for Gastric Cancer in Korea over the 16 years from 1999 to 2015
- Author:
Bang Wool EOM
1
;
Kyu Won JUNG
;
Young Joo WON
;
Young Woo KIM
Author Information
- Publication Type:Original Article
- Keywords: Gastric neoplasm; Patient compliance; Korea
- MeSH: Aged; Diagnosis; Humans; Incidence; Korea; Neoplasm Metastasis; Patient Compliance; Stomach Neoplasms; Survival Rate
- From:Journal of Gastric Cancer 2019;19(1):92-101
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: The aim of this study was to evaluate the trend of non-compliance with treatment (NCT) among gastric cancer patients in the Korean population. MATERIALS AND METHODS: Using data from the Korea Central Cancer Registry from 1999 to 2015, patients who did not receive any treatment for gastric cancer within 4 months after diagnosis were defined as the NCT group. The annual incidence rate, distributions according to age group and stage, and 5-year relative survival of the patients exhibiting NCT were analyzed. RESULTS: The number of NCT patients was 5,871 (30.6%) in 1999 and continuously decreased to 4,434 (15.3%) in 2015. Between 2006 and 2015, the proportions of NCT patients decreased from 72.9% to 55.0% among those 80 years old or older and from 9.2% to 5.4% among patients younger than 40 years. In patients with distant metastases, this proportion decreased from 35.5% to 32.7%, and this proportion also decreased from 17.6% to 8.2% among those with localized disease. The 5-year relative survival rates of NCT patients between 2011 and 2015 were significantly lower than those of the treated patients in each stage (60.2% vs. 99.7%, 13.8% vs. 67.1%, and 2.0% vs. 8.3% among those with localized, regional, and distant disease, respectively). CONCLUSIONS: The proportion of NCT gastric cancer patients has decreased during the last 16 years. However, considerable numbers of elderly patients are still NCT. There must be a strategy to decrease NCT and improve the nationwide survival rate of patients with gastric cancer.
